Webinar | The smarter PET Scan: AI's role in transforming Nuclear Medicine and Alzheimer's diagnosis & care

Nuclivision is hosting its first-ever webinar. We're thrilled to welcome Prof Silvia Morbelli for a clinical deep-dive into how AI is transforming PET imaging in Alzheimer's disease management and she is joined by our CEO Maarten Larmuseau exploring further what impact AI can have on PET scanning today and what's on the horizon.

Nuclivision attends the RSNA Annual Meeting in Chicago

Our CEO, Maarten Larmuseau, will attend the Annual Meeting of RSNA in Chicago at the end of November. He will have an oral and poster presentation highlighting the added value of AI image enhancement in low dose PET images.

BIR AI in NM & PET 2025

This November, our COO will attend BIR AI in NM & PET 2025 in Oxford, UK. This event showcases a range of AI use in nuclear medicine and PET and it has been designed to give a range of viewpoints including from technologists, physicists, clinicians and industry.

CE Approval for NUCLARITY

Ghent-based medtech company Nuclivision launches NUCLARITY, a CE-approved medical software that makes PET scans faster and safer. Following extensive clinical validation, the company has obtained CE marking as a class IIa medical device for its first product, enabling the growing team to enter the European market.

BELNUC 2025

Nuclivision presented new data on low-count PET imaging using Nuclarity at the BELNUC 2025 Symposium in Bruges. Both oral and poster presentations highlighted the software’s generalizability across tracers and clinical sites.

Nuclivision has raised a €5M seed round

We’re proud to announce the closing of our €5M seed round with HERAN Partners, LUMO Labs, and imec.istart future fund. Their trust, expertise, and capital will enable us to accelerate the commercialization of our PET image enhancement software, Nuclarity, across Europe and the US. This milestone also strengthens our commitment to continued innovation in the promising & growing field of nuclear medicine—driven by rising oncology volumes, radiotracer innovations, and the rise of theranostics. As one of the few software-first players, we’re uniquely positioned to make nuclear medicine safer, more affordable, and more accessible.

Nuclivision breakfast symposium at EANM 2025

Nuclivision attended the 38th Annual EANM Conference in Barcelona beginning of October. It was a celebratory edition as the community was not only celebrating 40 years of EANM but Nuclivision also highlighted the CE certification of their image enhancement software NUCLARITY during their first breakfast symposium hosting more than 30 clinicians and researchers enthusiastic to learn more about the power of AI in nuclear medicine.

Nuclivision featured in the news

Nuclivision was highlighted by Trends Kanaal Z as 'starter of the week', a category in their business magazine featuring promising startups.

Nuclivision attends EANM 2024 in Hamburg

Nuclivision will attend the 37th Annual EANM Congress to present research on PET image denoising and explore the latest innovations in AI, novel radiotracers, and theranostics, while connecting with industry leaders and startups.

Nuclivision achieves ISO 13485 certification

Nuclivision is now ISO 13485 certified, ensuring quality and safety in our medical imaging software development and operations.

Nuclivision joins wintercircus community

Selected out of 120 candidates, Nuclivision has secured a spot in the Ghent Wintercircus Community.

Best poster award AINM 2023

Nuclivision wins best poster award at the International Symposium on Artificial Intelligence in Nuclear Medicine in Groningen.